Randomized, Placebo-Controlled, Crossover Study of Methylphenidate for Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers with Developmental Disorders
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with pervasive developmental disorder (PDD) or intellectual disability (ID). METHODS: Fourteen preschoolers with developmental disorders (DD, n = 14; PDD, n = 12; ID, n = 2) underwent MPH titration in a single-blind manner followed by a 4-week double-blind crossover phase. Each child was administered placebo for 2 weeks and "optimal dose" for 2 weeks. The primary outcome measure was the Diagnostic and Statistical Manual of Mental Disorders, 4(th) edition (DSM-IV) ADHD subscale of the Conners' Parent Rating Scale-Revised (CPRS-R-DSM-IV-ADHD). RESULTS: MPH improved parent-rated ADHD symptoms of the preschoolers; 50% were rated as responders. The CPRS-R-DSM-IV-ADHD subscale was significant for the PDD subgroup (p = 0.005, Cohen d = 0.97) and marginally significant for the entire DD sample (p = 0.08, Cohen d = 0.50). Half of the preschoolers experienced side effects with MPH, including reports of increased stereotypic behavior, upset stomach, sleep-related difficulties, and emotional lability. One child discontinued during titration due to side effects. CONCLUSION: The predominant direction of response in these preschoolers with both ADHD and PDD/ID favored MPH, even though the response was more subtle and variable than in older and typically developing children. Due to high rates of adverse effects, preschoolers should be monitored closely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716 · cited 4×
“The outcome measures, CRS-R, Nisonger Child Behavior Rating Form (NCBRF) (Aman et al. 1996), CGAS (Shaffer et al. 1983), and CGI (Guy 1976) were obtained at screen, baseline, and at the weekly medication monitoring visits.”
InfluentialPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1088 · Cited by 652
Lecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569 · cited 2×
“…(DD), including pervasive developmental disorder (PDD) and intellectual disability (ID), often have symptoms of attention-deficit = hyperactivity disorder (ADHD) that limit the effectiveness of educational, behavioral, and other interventions (American Psychiatric Association 2000; Lecavalier 2006).”
Self-citation(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD
GREENHILL, L., KOLLINS, S., ABIKOFF, H., MCCRACKEN, J., RIDDLE, M., SWANSON, J., MCGOUGH, J., WIGAL, S., WIGAL, T., VITIELLO, B., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235077.32661.61 · Cited by 467 · cited 4×
“High rates of emotional lability were also reported in typically developing preschoolers treated with MPH (Greenhill et al. 2006).”
InfluentialSelf-citationMethylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?
Elia, J., Borcherding, B. G., Rapoport, J. L., & Keysor, C. S. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90126-a · Cited by 294
Medication use among children with autism spectrum disorders
Oswald, D. P., & Sonenklar, N. A. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.17303 · Cited by 195
Medication Patterns in Patients with Autism: Temporal, Regional, and Demographic Influences
Aman, M. G., Lam, K. S. L., & Van Bourgondien, M. E. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.116 · Cited by 174
Self-citationDi Martino, A., Melis, G., Cianchetti, C., & Zuddas, A. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649011 · Cited by 82 · cited 1×
“%) in the current study is consistent with the report of increased ste-reotypies after a single test dose of MPH in older children with PDD (Di Martino et al. 2004).”
Cited by
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Davis, N. O., & Kollins, S. H. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0126-9 · Cited by 156
The comorbidity of ADHD and autism spectrum disorder
Antshel, K. M., Zhang-James, Y., & Faraone, S. V. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.840417 · Cited by 147
Methylphenidate for children and adolescents with autism spectrum disorder
Sturman, N., Deckx, L., & van Driel, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011144.pub2 · Cited by 135
Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134
“…Mean dose Arnold et al. (2006) 16 9.3 75 Crossover 6 4 ATOM 44.2 mg/day Harfterkamp et al. (2012) 97 10.0 86 Parallel 10 5 ATOM 1.2 mg/kg day Ghuman et al. (2009) 12 4.8 93 Crossover 2 3 MPH .4 mg/kg/dose Handen et al. (2000) 13 7.4 77 Crossover 1 2 MPH .45 mg/kg/dose Quintana et al. (1995)…”
BackgroundMethodInfluentialRodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
Psychopharmacology in autism: an update
Canitano, R., & Scandurra, V. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.015 · Cited by 79
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Psychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Ghuman, J. K., & Ghuman, H. S. (2013) · Pediatric Drugs · doi:10.1007/s40272-012-0001-5 · Cited by 21
Self-citation
Metadata
- Authors
- Ghuman, J. K., Aman, M. G., Lecavalier, L., Riddle, M. A., Gelenberg, A., Wright, R., Rice, S., Ghuman, H. S., & Fort, C.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-08
- Volume
- 19
- Issue
- 4
- Pages
- 329-339
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2018911534
- Cited by
- 90
- References
- 10
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.